Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00041314
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin, gemcitabine, and exisulind in treating patients who have advanced non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/13/2023
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +78 locations
Conditions: Lung Cancer
Register for Updates
Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer
NCT00006004
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for treating non-small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/13/2023
Locations: Emory University Hospital - Atlanta, Atlanta, Georgia +15 locations
Conditions: Lung Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Bladder Cancer
NCT00003701
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether four-drug combination chemotherapy is more effective than two-drug combination chemotherapy in treating bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have bladder cancer.
Gender:
ALL
Ages:
Between 0 years and 120 years
Trial Updated:
06/13/2023
Locations: Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia +12 locations
Conditions: Bladder Cancer, Urethral Cancer
Register for Updates
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
NCT00632853
Active Not Recruiting
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/08/2023
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +933 locations
Conditions: Lung Cancer
Register for Updates
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
NCT02855944
Completed
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/07/2023
Locations: Rocky Mountain Cancer Center, Denver, Colorado +76 locations
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Register for Updates
A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
NCT02578641
Completed
This study is a multi-center, randomized, open label, Phase III clinical trial for advanced Nasopharyngeal Carcinoma(NPC) Patients. Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving an infusion of a person's cytotoxic T cells (CTL) that have been treated in the laboratory may help the body build an effective immune response to kill tumor cells. Giving co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2023
Locations: City of Hope National Medical Center, Duarte, California +29 locations
Conditions: Nasopharyngeal Carcinoma
Register for Updates
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
NCT01711541
Completed
This partially randomized phase I/II trial studies the side effects and best dose of veliparib when given together with combination chemotherapy and to see how well they work in treating patients with stage IV head and neck cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2023
Locations: Northwestern University, Chicago, Illinois +4 locations
Conditions: Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7
Register for Updates
Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
NCT02784288
Completed
Investigators will determine whether a treatment paradigm of up-front neck dissection, to more accurately pathologically stage patients, minimizing the number of treatment modalities in patients with low risk oropharyngeal squamous cell carcinoma, can improve quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2023
Locations: University of Michigan Cancer Center, Ann Arbor, Michigan
Conditions: Oropharyngeal Squamous Cell Cancer
Register for Updates
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT03077828
Active Not Recruiting
The purpose of this research study is to evaluate a new drug Pembrolizumab in combination with chemotherapy, for Relapsed/Refractory Hodgkin Lymphoma. The chemotherapy regimen is called "ICE" and includes three drugs: ifosfamide, carboplatin, and etoposide. Pembrolizumab is currently Food and Drug Administration (FDA) approved for the treatment of some patients with melanoma, lung cancer and head and neck cancer, but has not yet been approved for the treatment of Relapsed/Refractory Hodgkin Lymp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2023
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia +5 locations
Conditions: Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma, Recurrent Mixed Cellularity Classical Hodgkin Lymphoma, Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma, Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma, Refractory Mixed Cellularity Classical Hodgkin Lymphoma, Refractory Nodular Sclerosis Classical Hodgkin Lymphoma
Register for Updates
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
NCT03567720
Active Not Recruiting
This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO) plus electroporation (EP) in combination with pembrolizumab therapy. Cohort 2 will be a single-arm study of intratumoral TAVO-EP plus pembrolizumab along with treatment of an approved chemotherapy per standard of care (either nab-paclitaxel (Abraxane®) or gemcitabine (Gemzar®) plus carboplatin (Paraplatin®)) in participants with TNBC and no prior s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2023
Locations: University of Arizona, Tucson, Arizona +13 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer
NCT01004731
Completed
The objective is to evaluate the toxicity profile, response rate, and time to progression of Cetuximab administered in combination with either Carboplatin + Gemcitabine in patients with advanced non-small cell lung cancer with positive EGFr expression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/24/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Stage IV Non-small Cell Lung Cancer
Register for Updates
Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer
NCT03094884
Recruiting
Phase I study with the hypothesis that Pulsed Low Dose Radiation (PLDR) radiation delivery technique can significantly decrease the rate of severe acute esophagitis in patients receiving concurrent Chemo-radiation therapy (CRT) for non-small cell lung cancer or esophageal cancer while maintaining similar efficacy. For these patients, the rate of severe acute esophagitis during concurrent CRT is high (approximately 20%) when conventional external beam radiation is utilized. Severe acute esophagit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2023
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Lung Cancer, Esophageal Cancer
Register for Updates